
CLAIMS

1. A compound having formula (I):



(I)


or a pharmaceutically acceptable salt thereof, wherein


Ar is a 5- to 10-membered aromatic or heteroaromatic ring, optionally substituted with from one to three R^3;

L^1 is selected from the group consisting of a bond, $C_{1\text{-}6}$ alkylene, and $C_{1\text{-}6}$ heteroalkylene ,

L^2 is selected from the group consisting of a bond, $C_{1\text{-}6}$ alkylene, and $C_{1\text{-}6}$ heteroalkylene ,

Y is CO_2H or is selected from the group consisting of





tetrazolyl and tetrazolonyl, wherein the tetrazolyl or tetrazolonyl is optionally substituted with R,

wherein p is 0, 1 or 2 and wherein each R group is independently selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_1-C_6 hydroxyalkyl, C_1-C_6 alkoxy, or C_1-C_4 alkyl-O-C_1-C_4 alkyl;

each R^1 and each R^{2a} is independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, and C_{2-6} alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, OH, CN, C_{1-3} alkyl, C_{1-3} haloalkyl, and C_{1-3} alkoxy;

R^{2b} is selected from the group consisting of H, halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, and C_{2-6} alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C_{1-3} alkyl, C_{1-3} haloalkyl, and C_{1-3} alkoxy;


or optionally one R^{2a} and R^{2b} when on adjacent vertices of a phenyl ring, may be joined together to form a 5- or 6-membered heterocycloalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said heterocycloalkyl ring is optionally substituted with from one to three members selected from fluoro and C_{1-3} alkyl;

each R^3 is independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, and C_{2-6} alkenyl;

the subscript m is an integer of from 0 to 4; and

the subscript n is an integer of from 0 to 3.

2. The compound of claim **1**, having formula (I'):



(I')

or a pharmaceutically acceptable salt thereof, wherein

Ar is a 5- to 10-membered aromatic or heteroaromatic ring, optionally substituted with from one to three R^3;

L^1 is selected from the group consisting of a bond, C_{1-6} alkylene, and C_{1-6} heteroalkylene ,

L^2 is selected from the group consisting of a bond, C_{1-6} alkylene, and C_{1-6} heteroalkylene ,

each R^1 and each R^{2a} is independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, and C_{2-6} alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C_{1-3} alkyl, C_{1-3} haloalkyl, and C_{1-3} alkoxy;

R^{2b} is selected from the group consisting of H, halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-6} cycloalkyl, and C_{2-6} alkenyl, wherein the alkyl, cycloalkyl and alkenyl portions are optionally substituted with from one to three members selected from fluoro, CN, C_{1-3} alkyl, C_{1-3} haloalkyl, and C_{1-3} alkoxy;

or optionally one R^{2a} and R^{2b} when on adjacent vertices of a phenyl ring, may be joined together to form a 5- or 6-membered heterocycloalkyl ring having one or two ring vertices independently selected from O, N and S, wherein said heterocycloalkyl ring is optionally substituted with from one to three members selected from fluoro and C_{1-3} alkyl;


each R^3 is independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, and C_{2-6} alkenyl;

the subscript m is an integer of from 0 to 4; and

the subscript n is an integer of from 0 to 3.

3. A compound of claim **1**, wherein Y is selected from the group consisting of: tetrazolyl and tetrazolonyl, wherein the tetrazolyl or tetrazolonyl is optionally substituted with C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, -C_{1-6} alkoxy or C_{1-4}alkyl-O-C_{1-4}alkyl.


4. A compound of any one of claims **1**and **4** having the formula selected from the group consisting of:



and

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

5. A compound of any one of claims **1**to **4**, having the formula:



or a pharmaceutically acceptable salt thereof, wherein L^2 is C_{1-3} alkylene and wherein said compound is substantially free of other isomers.

6. A compound of any one of claims **1 to 5**, wherein Ar is selected from benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R^3.


7. A compound of any one of claims **1 to 4**, wherein L^1 is selected from the group consisting of a bond, -CH_2- and -$CH(CH_3)$-.

8. A compound of any one of claims **1 to 3**, wherein L^2 is selected from the group consisting of a bond, -O-CH_2-, -$CH(CH_3)$-, -$C(CH_3)_2$-, -CH_2CH_2-, -CH_2-, and -$CH_2CH_2CH_2$-.

9. A compound of any one of claims **1 to 8**, wherein n is 1 or 2.

10. A compound of any one of claims **1 to 9**, wherein m is 1, 2 or 3.

11. A compound of claim **1**, having the formula:



(Ia)


or a pharmaceutically acceptable salt thereof.

12. A compound of claim **11**, wherein Ar is selected from benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R^3.


13. A compound of claim **11** or **12**, wherein L^1 is selected from the group consisting of a bond, -CH_2- and -$CH(CH_3)$-.

14. A compound of any one of claim **11** to **13**, wherein L^2 is selected from the group consisting of a bond, -O-CH_2-, -$CH(CH_3)$-, -$C(CH_3)_2$-, -CH_2CH_2- , -CH_2-, and -$CH_2CH_2CH_2$-.

15. A compound of claim **11**, having a formula selected from the group consisting of:




(Ia1)



(Ia2)

and



(Ia3)

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

16. A compound of claim **15**, wherein Ar is selected from the group consisting of benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R^3.

17. A compound of claim **15** or **16**, wherein Ar is selected from the group consisting of 1,3-phenylene and 1,4-phenylene, each of which is optionally substituted with from one to two R^3.


18. A compound of any one of claims **15** to **17**, wherein L^1 is selected from the group consisting of a bond,$-CH_2-$ and $-CH(CH_3)-$.

19. A compound of any one of claims **15** to **18**, wherein L^2 is selected from the group consisting of $-O-CH_2-$, $-CH(CH_3)-$, $-C(CH_3)_2-$, $-CH_2CH_2-$, $-CH_2-$ and $-CH_2CH_2CH_2-$.


20. A compound of any one of claims **15** to **19**, wherein R^1 is selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{3-5} cycloalkyl, and C_{2-3} alkenyl.

21. A compound of any one of claims **15** to **19**, wherein R^1 is selected from the group consisting of chloro, methyl, cyano, ethyl, cyclopropyl, trifluoromethyl and trifluoromethoxy.

22. A compound of any one of claims **15** to **21**, having a formula selected from the group consisting of:




(Ia1')



(Ia2')


and



(Ia3')

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

23. A compound of claim **1**, having the formula:



(Ib)

or a pharmaceutically acceptable salt thereof.


24. A compound of claim **23**, wherein R^{2b} is hydrogen.

25. A compound of claim **23** or **24**, wherein Ar is selected from the group consisting of benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R^3.

26. A compound of any one of claims **23** to **25**, wherein L^1 is selected from the group consisting of a bond, $-CH_2-$ and $-CH(CH_3)-$.

27. A compound of any one of claims **23** to **26**, wherein L^2 is selected from the group consisting of a bond, -O-CH_2-, -$CH(CH_3)$-, -$C(CH_3)_2$-, -CH_2CH_2- , -CH_2- and - $CH_2CH_2CH_2$-.

28. A compound of any one of claims **23** to **27**, having a formula selected from the group consisting of:



(Ib1) (Ib2) and (Ib3)

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

29. A compound of claim **28**, wherein Ar is selected from the group consisting of benzene, pyridine and quinoline, each of which is optionally substituted with from one to two R^3.

30. A compound of claim **28** or **29**, wherein Ar is selected from the group consisting of 1,3-phenylene and 1,4-phenylene, each of which is optionally substituted with from one to two R^3.

31. A compound of any one of claims **28** to **30**, wherein R^3 is selected from the group consisting of CH_3, CH_2CH_3, $CH_2CH_2CH_3$ and $CH(CH_3)_2$.


32. A compound of any one of claims **28** to **31**, wherein L^1 is selected from the group consisting of a bond,-CH_2- and -$CH(CH_3)$-.

33. A compound of any one of claims **28** to **32**, wherein L^2 is selected from the group consisting of -O-CH_2-, -$CH(CH_3)$-, -$C(CH_3)_2$-, -CH_2CH_2-, -CH_2- and -$CH_2CH_2CH_2$-.


34. A compound of any one of claims **28** to **33**, wherein R^1 is selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, C_{3-5} cycloalkyl, and C_{2-3} alkenyl.

35. A compound of any one of claims **28** to **33**, wherein R^1 is selected from the group consisting of chloro, methyl, cyano, ethyl, cyclopropyl, trifluoromethyl and trifluoromethoxy.

36. A compound of claim **28**, having a formula selected from the group consisting of:




(Ib1')



(Ib2')

and




(Ib3')

or a pharmaceutically acceptable salt thereof, wherein said compound is substantially free of other isomers.

37. A compound of claim **1** or a pharmaceutically acceptable salt thereof, selected from Table 1 and having activity of ++ or +++.


38. A compound of claim **1** or a pharmaceutically acceptable salt thereof, selected from Table 1 and having activity of +++.

39. A compound of claim **1** or a pharmaceutically acceptable salt thereof, having the formula




.

40. A compound of claim **1** or a pharmaceutically acceptable salt thereof, having the formula



41. A compound of claim **1** or a pharmaceutically acceptable salt thereof, having the formula



42. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and at least one compound of any one of claim **1 to 41**, or a pharmaceutically acceptable salt thereof.

43. A compound of any one of claims **1 to 41** or a pharmaceutically acceptable salt thereof, for use in therapy.

44. Use of a compound of any one of claims **1 to 41** or a pharmaceutically acceptable salt thereof, in the optionally in admixture with a pharmaceutically acceptable excipient or carrier, in the preparation of a medicament for treating a CCR(9) mediated disease or condition selected from the group consisting of inflammatory bowel diseases, an allergic disease, psoriasis, atopic dermatitis, asthma, fibrotic diseases, graft rejection, immune mediated food allergies, autoimmune diseases, Celiac disease, rheumatoid arthritis, thymoma, thymic carcinoma, leukemia, Sjogren syndrome, GvHD (graft versus host disease), graft rejection, solid

tumor, or acute lymphocytic leukemia, melanoma, primary sclerosing cholangitis, hepatitis and inflammatory hepatic disease or post-operative ileus, Crohn's disease and ulcerative colitis; in a subject in need thereof.

45. Use in accordance with claim **44**, wherein said disease or condition is selected from the group consisting of inflammatory bowel diseases.

46. Use in accordance with claim **44**, wherein said disease or condition is selected from the group consisting of Crohn's disease and ulcerative colitis.